Clinical Studies
Backed by 20 years of research
Explore the results of CEFALY’s clinical studies
Discover the science behind CEFALY
Multiple clinical studies have shown that external trigeminal nerve stimulation (eTNS) for migraine is safe and effective, with no serious adverse side effects. Our medical advisory team continues to conduct new research, so we can learn more about migraine’s complex neurological pathways.
TEAM study
26%
of CEFALY users reported pain freedom after 2 hours of treatment
56.4%
of CEFALY users reported resolution of their most bothersome migraine symptom
42.5%
of CEFALY users reported resolution of all migraine symptoms
CEFALY provides effective acute migraine treatment at home
The Trial of eTNS for the Acute treatment of Migraine (TEAM) study found that the use of self-administered 2-hour eTNS therapy with CEFALY is a safe and effective therapeutic option, with or without the use of acute anti-migraine medications.
The TEAM study is the largest sham-controlled clinical trial examining the use of any e-TNS therapy for the treatment of migraine headache.
ACME study
59%
reduction in migraine pain intensity, on average, following one hour of treatment with CEFALY. This relief continued up to 24 hours
79%
of acute migraine sufferers saw pain relief
32%
of acute migraine sufferers saw pain freedom
CEFALY significantly reduces migraine pain
In the Acute Migraine Therapy with External Trigeminal Neurostimulation (ACME) study, patients saw a reduction in migraine pain intensity following a 60-minute ACUTE treatment session with CEFALY. This was a double-blind, randomized, sham-controlled study conducted across multiple headache centers in the U.S.
PREMICE study
38.1%
of CEFALY users saw at least a 50% reduction in the number of migraine days
30%
(mean 2.06) reduction in monthly migraine days among CEFALY users
74.6%
decrease in migraine medication intake among patients who responded to PREVENT treatment with CEFALY
CEFALY significantly decreases the number of migraine days
With compliant daily use of CEFALY’s 20-minute PREVENT treatment, patients experienced a significant reduction in the number of migraine days, the Migraine Prevention with a Supraorbital Transcutaneous Stimulator (PREMICE) study found.
Adverse events were mild and fully reversible within 20 minutes, without intervention. This was a double-blind, randomized, sham-controlled study conducted across multiple Belgian tertiary headache centers.
Help make life better for moms-to-be with migraine
Pregnant and living with headaches or migraine? Find out if you’re eligible to participate in the CEFALY Pregnancy Registry.